Hegi-Johnson, F., Rudd, S. E., Wichmann, C., Akhurst, T., Roselt, P., Trinh, J., John, T., Devereux, L., Donnelly, P. S., Hicks, R., Scott, A. M., Steinfort, D., Fox, S., Blyth, B., Parakh, S., Hanna, G. G., Callahan, J., Burbury, K., & MacManus, M. (2022). immunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol. BMJ open, 12(11), . http://access.bl.uk/ark:/81055/vdc_100169753272.0x000032